Compare Arm Holdings plc (ARM) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arm Holdings plc vs IDEXX Laboratories, Inc. — how do they compare? Arm Holdings plc trades at $269.09 (market cap $287.22B), while IDEXX Laboratories, Inc. trades at $571.66 (market cap $46.22B). The key difference: Arm Holdings plc is far larger — about 6.2× IDEXX Laboratories, Inc.'s market cap, and Arm Holdings plc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| ARM | IDXX | |
|---|---|---|
Market Cap | $287.22B | $46.22B |
Sector | Technology | Health |
52-Week High | $439.46 | $766.68 |
52-Week Low | $104.55 | $526.44 |
Enterprise Value | $283.79B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARM Holdings trades at $272.10, up 1.59% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported robust revenue growth, with fiscal 2025 revenue of $4.01 billion and net income of $792 million, and strong profitability margins. Analyst consensus is bullish with a 70.37% buy rating and a $329.80 price target, though valuation multiples remain elevated.
The outlook is positive given ARM's leadership in AI chip architecture and projected revenue growth to $5.2 billion in 2026. Key risks include high valuation multiples, smartphone market headwinds, and execution challenges in custom chip development. Upside potential exists if AI-driven demand continues, but investors should weigh growth prospects against premium pricing.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arm Holdings plc
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
